Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eslicarbazepine (Stedesa) can be used for adjunctive therapy for adults with partial-onset seizures.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 80.00 | |
25 mg | In stock | $ 155.00 | |
50 mg | In stock | $ 239.00 | |
100 mg | In stock | $ 372.00 | |
200 mg | In stock | $ 549.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 52.00 |
Description | Eslicarbazepine (Stedesa) can be used for adjunctive therapy for adults with partial-onset seizures. |
In vitro | Eslicarbazepine is an anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. Eslicarbazepine acetate is a prodrug for eslicarbazepine (S-licarbazepine), which is a dual Inhibitor of β-Secretase and voltage-gated sodium channel[1][2]. |
Synonyms | Pazzul, EC 810-248-9, BIA 2-194, Stedesa, Erelib |
Molecular Weight | 254.28 |
Formula | C15H14N2O2 |
CAS No. | 104746-04-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12 mg/mL (47.19 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Eslicarbazepine 104746-04-5 Membrane transporter/Ion channel Neuroscience Sodium Channel Beta-Secretase Pazzul Inhibitor EC 810-248-9 inhibit BIA 2-194 Stedesa Erelib inhibitor